share_log

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co.重申對Indaptus Therapeutics的買入,維持12美元的目標股價
Benzinga ·  2023/08/15 06:55

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $12 price target.

HC Wainwright&Co.分析師Raghuram Selvaraju重申Indaptus Treateutics(納斯達克:INDP)的買入,並維持12美元的目標價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論